RareResearch.AI
← Back to atlas

c.1525_1539del

In-frame indelI3Pathogenic/Likely pathogenicTransmembrane · predicted
In-frame indel variant · indel site at position 509 · Transmembrane helix 7 · WFS1 (Wolframin)

I3 — Multi-residue in-frame indel — likely major structural disruption

Wild-type vs Modified Structure

Wild-type · full length
Wild-type wolframin · 890 aa — AlphaFold reference
Fullscreen ↗
Modified product
Modified product · c.1525_1539del — Cα-RMSD 3.48 Å vs WT (folded core)
Fullscreen ↗

Left: full-length wild-type wolframin (890 aa). Right: the ColabFold (AlphaFold2) prediction of the 5-aa in-frame deletion product — the affected region near residue 509 (Transmembrane helix 7) is highlighted in both panes. Backbone Cα-RMSD over the folded core is 3.48 Å.

Variant Assessment

Variant type
In-frame indel
Schema
I3
Multi-residue in-frame indel — likely major structural disruption
Domain
Transmembrane helix 7
Backbone Cα-RMSD
3.48 Å
vs WT · folded core (n=320)

Modified-sequence structure resolved. The 5-aa in-frame deletion was modeled with ColabFold (AlphaFold2, full-MSA; mean pLDDT 69.2) and superposed on the wild-type AlphaFold model. Kabsch-superposed Cα-RMSD over high-confidence (WT pLDDT>70) residues N-terminal to the lesion; cross-pipeline, includes ~few-Å method baseline

Therapeutic Implication · I3

5 residues removed in frame around position 509 (Transmembrane helix 7). A change this size usually perturbs local packing and can propagate to the fold. Gene therapy is the primary path unless an AlphaFold prediction of the modified sequence shows a surprisingly intact fold. Predicted structure pending (ColabFold).

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; Wolfram syndrome 1; Type 2 diabetes mellitus; Wolfram-like syndrome; Cataract 41
Population frequency (gnomAD v4)Ultra-rare · AF 0.0016%
cDNA changec.1525_1539del
ClinVar variantNM_006005.3(WFS1):c.1525_1539del (p.Val509_Tyr513del)
ClinVar accessionVCV001453842
Last evaluated2024/09/22 00:00

Observed at very low frequency in gnomAD.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the c.1525_1539del card below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals matched to this I3 in-frame indel variant and its domain context.

Download c.1525_1539del PDF card ↓or markdown ↓

Full Variant Card

c.1525_1539del — WFS1 Molecular Atlas Card

Variant type: In-frame indel Change: 5 residue(s) deleted in frame at position 509 Domain context: Transmembrane helix 7

Schema category: I3 — Multi-residue in-frame indel — likely major structural disruption

5 residues removed in frame around position 509 (Transmembrane helix 7). A change this size usually perturbs local packing and can propagate to the fold. Gene therapy is the primary path unless an AlphaFold prediction of the modified sequence shows a surprisingly intact fold. Predicted structure pending (ColabFold).

Structural prediction

  • Reading frame: preserved (in-frame) — no premature stop, NMD does not apply.
  • Affected domain: Transmembrane helix 7
  • Predicted modified structure: pending — AlphaFold/ColabFold prediction of the modified sequence and backbone-RMSD vs wild-type backfill here (Wave 2).

Clinical evidence

  • Classification: Pathogenic/Likely pathogenic
  • Review status: criteria provided, multiple submitters, no conflicts
  • Associated conditions: Autosomal dominant nonsyndromic hearing loss 6; Wolfram syndrome 1; Type 2 diabetes mellitus; Wolfram-like syndrome; Cataract 41
  • cDNA change: c.1525_1539del
  • ClinVar accession: VCV001453842
  • Last evaluated: 2024/09/22 00:00
  • Submissions: 1

Card generated by wolfram-atlas-batch (in-frame indel pipeline) on 2026-06-08T02:41:21.492262Z. Schema: reference/card_schema_extension.md (I1–I3). WFS1: UniProt O76024, AlphaFold v6.